{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:23:10Z","timestamp":1793413390760,"version":"4.5.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1645,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>Spontaneous reactivation of chronic hepatitis B (CHB) is an important cause of acute-on-chronic liver failure (ACLF). Antiviral drugs may help reduce the high morbidity and mortality in such patients, especially in places where liver transplant is not available. The aim was to evaluate the efficacy of tenofovir and to determine the predictors of mortality in patients with spontaneous reactivation of CHB with ACLF. Consecutive patients of ACLF due to spontaneous reactivation of CHB were randomized to receive either tenofovir or placebo. The primary endpoint was survival at 3 months. Of the 90 patients with ACLF of different etiologies, 27 (26%) were due to reactivation of CHB and were enrolled. The median baseline hepatitis B virus (HBV) DNA level was 9 \u00d7 105 IU\/mL. Fourteen patients received tenofovir and 13 placebo. At 3 months the probability of survival was higher in the tenofovir than the placebo group (8\/14 [57%] versus 2\/13 [15%], respectively;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.03). The cause of death in the 15 patients was progressive liver failure leading to multiorgan failure. Liver transplantation could not be offered due to its nonavailability. In the surviving patients, there was a significant improvement in the Child-Turcotte Pugh (CTP) and model for endstage liver disease (MELD) scores and significant decline in the HBV DNA levels in the tenofovir group, whereas these parameters did not change significantly in the placebo group. More than 2 log reduction in HBV DNA levels at 2 weeks was found to be an independent predictor of survival.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Tenofovir significantly reduces HBV-DNA levels, improves CTP and MELD scores, and reduces mortality in patients with severe spontaneous reactivation of CHB presenting as ACLF. Reduction in HBV-DNA levels at 2 weeks should be a desirable goal and is a good predictor of survival. (Hepatology 2011;.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.24109","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T21:00:07Z","timestamp":1292360407000},"page":"774-780","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":230,"title":["Tenofovir Improves the Outcome in Patients with Spontaneous Reactivation of Hepatitis B Presenting as Acute-On-Chronic Liver Failure \u00a7\u0394"],"prefix":"10.1097","volume":"53","author":[{"given":"Hitendra","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barjesh Chander","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20250207","doi-asserted-by":"crossref","first-page":"153161","DOI":"10.1055\/s-2006-939753","article-title":"Hepatocellular carcinoma and hepatitis B virus.","volume":"26","author":"Chan","year":"2006","journal-title":"Semin Liver Dis"},{"key":"R2-8-20250207","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1016\/0168-8278(90)90069-4","article-title":"Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology.","volume":"10","author":"Lok","year":"1990","journal-title":"J Hepatol"},{"key":"R3-8-20250207","doi-asserted-by":"crossref","first-page":"732735","DOI":"10.1016\/0016-5085(85)90566-9","article-title":"Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis.","volume":"89","author":"Sheen","year":"1985","journal-title":"Gastroenterology"},{"key":"R4-8-20250207","doi-asserted-by":"crossref","first-page":"269282","DOI":"10.1007\/s12072-008-9106-x","article-title":"Acuteonchronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL).","volume":"3","author":"Sarin","year":"2009","journal-title":"Hepatol Int"},{"key":"R5-8-20250207","doi-asserted-by":"crossref","first-page":"11791197","DOI":"10.1002\/hep.20703","article-title":"AASLD position paper: the management of acute liver failure.","volume":"41","author":"Polson","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R6-8-20250207","doi-asserted-by":"crossref","first-page":"424428","DOI":"10.1046\/j.1365-2893.2002.00385.x","article-title":"The role of lamivudine and predictors of mortality in severe flareup of chronic hepatitis B with jaundice.","volume":"9","author":"Chan","year":"2002","journal-title":"J Viral Hepat"},{"key":"R7-8-20250207","doi-asserted-by":"crossref","first-page":"594599","DOI":"10.1007\/s10620-006-3175-2","article-title":"Differentiating acute hepatitis B from the first episode of symptomatic exacerbation of chronic hepatitis B.","volume":"51","author":"Kumar","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R8-8-20250207","doi-asserted-by":"crossref","first-page":"17371744","DOI":"10.1046\/j.1365-2036.2001.01107.x","article-title":"Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection.","volume":"15","author":"Tsang","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-8-20250207","doi-asserted-by":"crossref","first-page":"424428","DOI":"10.1046\/j.1365-2893.2002.00385.x","article-title":"The role of lamivudine and predictors of mortality in severe flareup of chronic hepatitis B with jaundice.","volume":"9","author":"Chan","year":"2002","journal-title":"J Viral Hepat"},{"key":"R10-8-20250207","doi-asserted-by":"crossref","first-page":"426432","DOI":"10.1111\/j.1440-1746.2004.03534.x","article-title":"Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.","volume":"20","author":"Tsubota","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"R11-8-20250207","doi-asserted-by":"crossref","first-page":"322327","DOI":"10.1016\/S0168-8278(02)00419-1","article-title":"The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.","volume":"38","author":"Chien","year":"2003","journal-title":"J Hepatol"},{"key":"R13-8-20250207","doi-asserted-by":"crossref","first-page":"309313","DOI":"10.1002\/hep.21307","article-title":"Tenofovir disoproxil fumarate: role in hepatitis B treatment.","volume":"44","author":"Wong","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R14-8-20250207","doi-asserted-by":"crossref","first-page":"548555","DOI":"10.1002\/hep.21055","article-title":"Antihepatitis B virus efficacy of tenofovir disoproxil fumarate in HIVinfected patients.","volume":"43","author":"Benhamou","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R15-8-20250207","doi-asserted-by":"crossref","first-page":"97101","DOI":"10.1002\/hep.21486","article-title":"A randomized controlled trial of lamivudine to treat acute hepatitis B.","volume":"45","author":"Kumar","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R16-8-20250207","doi-asserted-by":"crossref","first-page":"244255","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"R17-8-20250207","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1002\/hep.23246","article-title":"Longterm efficacy of tenofovir monotherapy for hepatitis B virusmonoinfected patients after failure of nucleosidenucleotide analogues.","volume":"51","author":"Van Bommel","year":"2010","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.24109","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201103000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:58:21Z","timestamp":1738947501000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201103000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.24109","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}